Ovarian Cancer
FDA Grants Accelerated Approval to Avmapki Fakzynja Co-pack for Some Ovarian Cancers
The FDA granted accelerated approval to the combination of avutometinib and defactinib (Avmapki Fakzynja Co-pack, ...
MAY 8, 2025
First and Only Ready-to-Dilute, Multi-Dose Vial of Thiotepa Approved
Shorla Oncology, a U.S.-Ireland specialty pharmaceutical company, announced that the FDA has granted approval for ...
MAY 8, 2025
Elahere Fully Approved for Certain Ovarian, Fallopian Tube or Primary Peritoneal Cancer
The FDA approved mirvetuximab soravtansine-gynx (Elahere, ImmunoGen, Inc. [now a part of AbbVie]) for adult ...
MARCH 25, 2024
Gynecologic Cancer Misinformation Prevalent on TikTok
Gynecologic cancer–related content on the TikTok social media platform is of poor educational quality, and ...
OCTOBER 6, 2023
OS Benefit in Platinum-Resistant Ovarian Cancer Shown for First Time
For the first time in a multicenter phase 3 trial, an overall survival (OS) benefit was provided by one therapy ...
JULY 10, 2023
Trastuzumab Deruxtecan Demonstrates Benefit Across an Array of HER2-Expressing Tumors
The antibody–drug conjugate trastuzumab deruxtecan (T-DXd) (Enhertu, Daiichi Sankyo/AstraZeneca) is emerging ...
JULY 7, 2023
Botensilimab Plus Balstilimab Improves Outcomes in Recurrent Platinum-Resistant/-Refractory Ovarian Cancer
In patients with recurrent platinum-resistant/-refractory ovarian cancer, treatment with botensilimab (Agenus), a ...
APRIL 26, 2023
FDA Approves Elahere to Treat Platinum-Resistant Ovarian Cancer
Mirvetuximab soravtansine-gynx (Elahere, ImmunoGen) was approved to treat adults with folate receptor ...
NOVEMBER 23, 2022
Circulating Extracellular Vesicle Biomarkers May Detect Early-Stage Cancers
A “liquid biopsy” that identifies tumor protein biomarkers found in circulating extracellular vesicles ...
APRIL 19, 2022
Meta-Analysis Explores AML and MDS Risk of PARP Inhibitors
A meta-analysis has found that use of PARP inhibitors increases the risk for myelodysplastic syndrome and acute ...
MARCH 19, 2021
FDA Grants New Indication for Zejula
The FDA approved a new indication for niraparib, an oral, once-daily poly PARP inhibitor, as a monotherapy ...
MAY 8, 2020
Zejula Monotherapy Approved for Some Late-Line Gyn Cancers
The FDA granted approval for an expanded indication for the poly(adenosine diphosphate–ribose) polymerase ...
OCTOBER 28, 2019
